



BETA DRUGS LIMITED

BDL/PKL/SEC/2019
12th October, 2019

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400051

Subject: SYMBOL: BETA

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations 2015 for the half year ended 30th September, 2019.

Dear Sir, / Madam,

With reference to the captioned subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(8) of SEBI (LODR) Regulations, 2015 for the half year ended 30th September, 2019.

This is for your information and necessary records.

Thanking you,
Yours faithfully,
For Beta Drugs limited,

V.K. Batra
Vijay Kumar Batra
Managing Director

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mkt'd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com



BETA DRUGS LIMITED

STATEMENT OF DEVIATION(S) OR VARIATION(S) UNDER REGULATION 32(1) OF SEBI (LODR) REGULATIONS 2015

In reference to the compliance under regulation 32(1) (3) & (b) of SEBI (LODR) Regulations 2015. As required under regulation 32(8) of SEBI (LODR) Regulations 2015, the company hereby submit to the Stock Exchange statements of deviation(s) or variation(s) for the half year ended on **30th September, 2019** for the initial public offer (IPO) & Preferential issue vide private placement offer cum application letter serial no. 01/2019 dated 24th April, 2019.

(a) Indicating Deviation(s), if any, in the use of proceeds from the object stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;

We hereby inform you that there was no deviation in the utilization of the proceeds of the public issue from the objects stated in the prospectus of the issue & private placement offer cum application letter serial no. 01/2019 dated 24th April, 2019, as required under regulation 32(1) (a) of SEBI (LODR) Regulations 2015.

(b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds;

We hereby inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 19th September, 2017 issued for Initial Public offering of Securities & private placement offer cum application letter serial no. 01/2019 dated 24th April, 2019 as per Regulation 32(1)(b') of SEBI (LODR) Regulations 2015.

Thanking you,
Yours faithfully,
For Beta Drugs Limited

Vijay Kumar Batra
Managing Director

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Export & Mktd Office : 1101, 11th Floor, Peninsula Park, Andheri West, Mumbai - 400053, Phone No. : +91-022-62360443

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com
www.adleylab.com

E-Mail :- info@betadrugslimited.com
sales@adleylab.com